Ilinca Serbanescu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ilinca Serbanescu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Ingo Zobel
Psychology School at the Fresenius University of Applied Sciences Berlin, Berlin, Germany
4 shared publicationsElisabeth Schramm
Department of Psychiatry and Psychotherapy, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
3 shared publicationsMatthias Backenstrass
Department of Clinical Psychology and Psychotherapy, University of Heidelberg, Heidelberg, Germany
3 shared publicationsSarah Drost
Department of Psychiatry and Psychotherapy, CBASP Center of Competence, University Medical Center Bonn, Bonn, Germany
3 shared publicationsBernd Weber
Department of Clinical Psychology and Psychotherapy, University of Heidelberg, Heidelberg, Germany
2 shared publicationsDieter Schoepf
Department of Psychiatry and Psychotherapy, CBASP Center of Competence, University Medical Center Bonn, Bonn, Germany
2 shared publications
Latest Publications
- Open Access
- 22 August 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (3) , 723-737
Identifying subgroups with differential response to CBASP versus Escitalopram during the first eight weeks of treatment in outpatients with persistent depressive disorder
There exists little empirical evidence helping clinicians to select the most effective treatment for individual patients with persistent depressive disorder (PDD). This study identifies and characterizes subgroups of patients with PDD who are likely to benefit more from an acute treatment with psychotherapy than from pharmacotherapy and vice versa. Non-medicated outpatients with PDD were randomized to eight weeks of acute treatment with the Cognitive Behavioral Analysis System of Psychotherapy (CBASP; n = 29) or escitalopram plus clinical management (ESC/CM; n = 31). We combined several baseline variables to one composite moderator and identified two subgroups of patients: for 56.0%, ESC/CM was associated with a greater reduction in depression severity than CBASP, for the remaining 44.0%, it was the other way around. Patients likely to benefit more from ESC/CM were more often female, had higher rates of moderate-to-severe childhood trauma, more adverse life events and more previous suicide attempts. Patients likely to benefit more from CBASP were older, had more often an early illness onset and more previous treatments with antidepressants. Symptomatic response, remission, and reductions in symptom severity occurred more often in those patients treated with their likely more effective treatment condition. The findings suggest that the baseline phenotype of patients with PDD moderates their benefit from acute treatment with CBASP relative to ESC/CM. Once confirmed in an independent sample, these results could serve to guide the choice between primarily psychotherapeutic or pharmacological treatments for outpatients with PDD.
- 22 August 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (3) , 723-737
Open AccessIdentifying subgroups with differential response to CBASP versus Escitalopram during the first eight weeks of treatment in outpatients with persistent depressive disorder
There exists little empirical evidence helping clinicians to select the most effective treatment for individual patients with persistent depressive disorder (PDD). This study identifies and characterizes subgroups of patients with PDD who are likely to benefit more from an acute treatment with psychotherapy than from pharmacotherapy and vice versa. Non-medicated outpatients with PDD were randomized to eight weeks of acute treatment with the Cognitive Behavioral Analysis System of Psychotherapy (CBASP; n = 29) or escitalopram plus clinical management (ESC/CM; n = 31). We combined several baseline variables to one composite moderator and identified two subgroups of patients: for 56.0%, ESC/CM was associated with a greater reduction in depression severity than CBASP, for the remaining 44.0%, it was the other way around. Patients likely to benefit more from ESC/CM were more often female, had higher rates of moderate-to-severe childhood trauma, more adverse life events and more previous suicide attempts. Patients likely to benefit more from CBASP were older, had more often an early illness onset and more previous treatments with antidepressants. Symptomatic response, remission, and reductions in symptom severity occurred more often in those patients treated with their likely more effective treatment condition. The findings suggest that the baseline phenotype of patients with PDD moderates their benefit from acute treatment with CBASP relative to ESC/CM. Once confirmed in an independent sample, these results could serve to guide the choice between primarily psychotherapeutic or pharmacological treatments for outpatients with PDD.
- Open Access
- 1 July 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 290, 378-386
Workplace interventions to reduce depression and anxiety in small and medium-sized enterprises: A systematic review
- 1 July 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 290, 378-386
Open AccessWorkplace interventions to reduce depression and anxiety in small and medium-sized enterprises: A systematic review
- Open Access
- 21 December 2020
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11
Impact of Baseline Characteristics on the Effectiveness of Disorder-Specific Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and Supportive Psychotherapy in Outpatient Treatment for Persistent Depressive Disorder
Importance: In the treatment of persistent depressive disorder (PDD), disorder-specific Cognitive Behavioral Analysis System of Psychotherapy (CBASP) has been shown to be superior to Supportive Psychotherapy (SP) in outpatients. It remains to clear which subgroups of patients benefit equally and differentially from both psychotherapies.Objective: To identify those patient-level baseline characteristics that predict a comparable treatment effectiveness of CBASP and SP and those that moderate the differential effectiveness of CBASP compared to SP.Design, setting and participants: In this analysis of a 48-week multicenter randomized clinical trial comparing CBASP to SP in adult antidepressant-free outpatients with early-onset PDD, we evaluated baseline variables from the following domains as potential predictors and moderators of treatment effectiveness: socio-demography, clinical status, psychosocial and global functioning, life quality, interpersonal problems, childhood trauma, treatment history, preference for psychotherapy, and treatment expectancy.Interventions: A 48-week treatment program with 32 sessions of either CBASP or SP.Main outcomes and measures: Depression severity measured by the 24-item Hamilton Rating Scale for Depression (HRSD-24) at week 48.Results: From N = 268 randomized outpatients, N = 209 completed the 48-week treatment program. CBASP completers had significantly lower post-treatment HRSD-24 scores than SP completers (meanCBASP=13.96, sdCBASP= 9.56; meanSP= 16.69, sdSP= 9.87; p = 0.04). A poor response to both therapies was predicted by higher baseline levels of clinician-rated depression, elevated suicidality, comorbid anxiety, lower social functioning, higher social inhibition, moderate-to-severe early emotional or sexual abuse, no preference for psychotherapy, and the history of at least one previous inpatient treatment. Moderator analyses revealed that patients with higher baseline levels of self-rated depression, comorbidity of at least one Axis-I disorder, self-reported moderate-to-severe early emotional or physical neglect, or at least one previous antidepressant treatment, had a significantly lower post-treatment depression severity with CBASP compared to SP (all p < 0.05).Conclusions and relevance: A complex multifactorial interaction between severe symptoms of depression, suicidality, and traumatic childhood experiences characterized by abuse, social inhibition, and anxiety may represent the basis of non-response to psychotherapy in patients with early onset PDD. Specific psychotherapy with CBASP might, however, be more effective and recommendable for a variety of particularly burdened patients compared to SP.
- 21 December 2020
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11
Open AccessImpact of Baseline Characteristics on the Effectiveness of Disorder-Specific Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and Supportive Psychotherapy in Outpatient Treatment for Persistent Depressive Disorder
Importance: In the treatment of persistent depressive disorder (PDD), disorder-specific Cognitive Behavioral Analysis System of Psychotherapy (CBASP) has been shown to be superior to Supportive Psychotherapy (SP) in outpatients. It remains to clear which subgroups of patients benefit equally and differentially from both psychotherapies.Objective: To identify those patient-level baseline characteristics that predict a comparable treatment effectiveness of CBASP and SP and those that moderate the differential effectiveness of CBASP compared to SP.Design, setting and participants: In this analysis of a 48-week multicenter randomized clinical trial comparing CBASP to SP in adult antidepressant-free outpatients with early-onset PDD, we evaluated baseline variables from the following domains as potential predictors and moderators of treatment effectiveness: socio-demography, clinical status, psychosocial and global functioning, life quality, interpersonal problems, childhood trauma, treatment history, preference for psychotherapy, and treatment expectancy.Interventions: A 48-week treatment program with 32 sessions of either CBASP or SP.Main outcomes and measures: Depression severity measured by the 24-item Hamilton Rating Scale for Depression (HRSD-24) at week 48.Results: From N = 268 randomized outpatients, N = 209 completed the 48-week treatment program. CBASP completers had significantly lower post-treatment HRSD-24 scores than SP completers (meanCBASP=13.96, sdCBASP= 9.56; meanSP= 16.69, sdSP= 9.87; p = 0.04). A poor response to both therapies was predicted by higher baseline levels of clinician-rated depression, elevated suicidality, comorbid anxiety, lower social functioning, higher social inhibition, moderate-to-severe early emotional or sexual abuse, no preference for psychotherapy, and the history of at least one previous inpatient treatment. Moderator analyses revealed that patients with higher baseline levels of self-rated depression, comorbidity of at least one Axis-I disorder, self-reported moderate-to-severe early emotional or physical neglect, or at least one previous antidepressant treatment, had a significantly lower post-treatment depression severity with CBASP compared to SP (all p < 0.05).Conclusions and relevance: A complex multifactorial interaction between severe symptoms of depression, suicidality, and traumatic childhood experiences characterized by abuse, social inhibition, and anxiety may represent the basis of non-response to psychotherapy in patients with early onset PDD. Specific psychotherapy with CBASP might, however, be more effective and recommendable for a variety of particularly burdened patients compared to SP.
- Top Cited PapersOpen Access
- 1 January 2017
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 74 (1) , 47-55
Altered Brain Activity in Unipolar Depression Revisited
Unipolar depression (UD) is one of the leading causes of disease burden worldwide.1 In line with the characteristic symptoms of low mood and reduced activity and concentration,2 patients with UD show impairments of emotional and cognitive processing.3,4 Numerous neuroimaging experiments5-8 have investigated the neural correlates underlying these impairments, but their results vary considerably. This variance might be attributable to sampling effects in this heterogeneous disorder but also to the high degree of experimental and analytic flexibility in neuroimaging. Consequently, several quantitative meta-analyses have been performed to delineate brain regions consistently implicated in UD9-14 (Figure 1 illustrates the different steps of a meta-analysis). However, these meta-analyses also yielded inconsistent findings (Figure 2).
- 1 January 2017
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 74 (1) , 47-55
Top Cited PapersOpen AccessAltered Brain Activity in Unipolar Depression Revisited
Unipolar depression (UD) is one of the leading causes of disease burden worldwide.1 In line with the characteristic symptoms of low mood and reduced activity and concentration,2 patients with UD show impairments of emotional and cognitive processing.3,4 Numerous neuroimaging experiments5-8 have investigated the neural correlates underlying these impairments, but their results vary considerably. This variance might be attributable to sampling effects in this heterogeneous disorder but also to the high degree of experimental and analytic flexibility in neuroimaging. Consequently, several quantitative meta-analyses have been performed to delineate brain regions consistently implicated in UD9-14 (Figure 1 illustrates the different steps of a meta-analysis). However, these meta-analyses also yielded inconsistent findings (Figure 2).
- 1 June 2016
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 24 (2) , 124-126
Psychische Störungen bei Patienten mit chronischen körperlichen Erkrankungen
Zusammenfassung: Klinische und epidemiologische Studien belegen, dass psychische Störungen häufige Begleiterscheinungen chronischer körperlicher Erkrankungen darstellen. Obwohl die rechtzeitige und korrekte Erkennung der somatopsychischen Komorbidität bedeutsame Implikationen für die Therapie und den Verlauf der assoziierten Erkrankungen hat, findet sie nur in einem begrenzten Teil der Fälle statt. Dabei kann eine frühzeitige Diagnostik und Behandlung der komorbiden psychischen Störung das Ausmaß ihrer Symptomatik verringern und die Lebensqualität der doppeltbelasteten Patienten entscheidend verbessern.
- 1 June 2016
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 24 (2) , 124-126
Psychische Störungen bei Patienten mit chronischen körperlichen Erkrankungen
Zusammenfassung: Klinische und epidemiologische Studien belegen, dass psychische Störungen häufige Begleiterscheinungen chronischer körperlicher Erkrankungen darstellen. Obwohl die rechtzeitige und korrekte Erkennung der somatopsychischen Komorbidität bedeutsame Implikationen für die Therapie und den Verlauf der assoziierten Erkrankungen hat, findet sie nur in einem begrenzten Teil der Fälle statt. Dabei kann eine frühzeitige Diagnostik und Behandlung der komorbiden psychischen Störung das Ausmaß ihrer Symptomatik verringern und die Lebensqualität der doppeltbelasteten Patienten entscheidend verbessern.